Dishman Carbogen Amcis Ltd. benchmarking: Perfomance to industry peers

Financial

	Dishman Carbogen Amc	Sun Pharma Adv. Res	Zenotech Laboratorie
Operational Metrics
Pharmaceuticals
US DMF Filings	18.0 .	n/a	n/a
Total reactor capacity	1150.0 kL	n/a	n/a
R&D as a % of Total Sales	1.64 %	576.14 %	n/a
Financials
5 yr Average ROE	-1.15 %	-64.48 %	9.5 %
5yr average Equity Multiplier	1.61	1.39	1.13
5yr Average Asset Turnover Ratio	0.26	0.22	0.36
5yr Avg Net Profit Margin	-2.96 %	-361.01 %	-13.89 %
Price to Book	0.55	0.0	2.87
P/E	25.7	0.0	89.89
5yr Avg Cash Conversion Cycle	24.66 Days	80.33 Days	-1217.81 Days
Inventory Days	110.18 Days	0.0	145.01 Days
Days Receivable	77.38 Days	80.33 Days	61.38 Days
Days Payable	156.95 Days	0.0	477.06 Days
5yr Average Interest Coverage Ratio	0.4	-97.45	-4.03
5yr Avg ROCE	0.91 %	208.61 %	9.71 %
5yr Avg Operating Profit Margin	13.93 %	-357.39 %	5.56 %
5 yr average Debt to Equity	0.3	-0.27	0.04
5yr CAGR Net Profit	n/a	9.0 %	n/a
5yr Average Return on Assets	-0.73 %	-68.32 %	8.4 %
Shareholdings
Promoter Holding	59.32 %	65.67 %	68.84 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.0	-3.42 %	0.0
Change in Mutual Fund Holding (3 Yrs)	-3.18 %	0.77 %	0.0

	Dishman Carbogen Amc	Sun Pharma Adv. Res	Zenotech Laboratorie
Product Wise Break-Up	Product Wise Break-Up Contract Research & Contract Manufacturing (CRAMS) 68.3 Cholesterol & Vit D Analogues 16.9 API 11.2 Quats & Generics 3.6 Marketable Molecules 0 R&D Services 0 Lease rental income 0 Sale of Oncology Products 0 0	Product Wise Break-Up Quats & Generics 0 Cholesterol & Vit D Analogues 0 Research and Development 100.0 0 Lease rental income 0 Sale of Oncology Products 0 0 API 0 Marketable Molecules 0	Product Wise Break-Up Quats & Generics 0 Cholesterol & Vit D Analogues 0 R&D Services 0 0 Lease rental 9.46 Sale of Oncology Products 0 Services- Contract Manufacturing 90.54 API 0 Marketable Molecules 0
Segment Break-Up	Segment Break-Up Carbogen Amcis 60.07 Others 39.93	-	-
Location Wise Break-Up	Location Wise Break-Up Rest of the World 98.29 India 1.71	Location Wise Break-Up Rest of the World 2.35 India 97.65	-
Operating Profit Break-Up	Operating Profit Break-Up Others 100	-	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up Non-APIs / Intermediates 31.68 Oncology 20.79 Ophthalmology 17.82 Hormones 13.86 Pain Management 3.96 Blood Related 3.96 Antibiotics 3.96 ADC-Warhead / ADC 3.96 Others 0.01	-	-